Celularity (CELU) vs Tevogen (TVGN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Celularity (CELU) has outperformed Tevogen (TVGN) over the past year, losing 32.1% versus a loss of 80.5%. Celularity is the larger company by market cap ($49.6 million vs $46.6 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CELU | TVGN |
|---|---|---|
| Share price | $1.53 | $7.15 |
| Market cap | $49.65M | $46.56M |
| 1-day change | +4.79% | +1.27% |
| YTD return | +31.53% | -57.34% |
| 1-year return | -32.09% | -80.50% |
| 5-year return | -97.97% | — |
| EPS (TTM) | $-2.73 | $-6.74 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $2.55 | $39.00 |
| 52-week low | $0.56 | $3.64 |
| Distance from 52-week high | -40.00% | -81.67% |
| Average volume | 3.89M | 10.03K |
| Shares outstanding | 32.45M | 6.51M |
| Employees | 115 | 18 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- CELU has outperformed TVGN by 48.4 percentage points over the past year.
About Celularity
CELU stock →Celularity Inc., a cellular and regenerative medicine company, focuses on addressing aging-related disease using novel therapies. The company operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking.
Health Care · Biotechnology: Pharmaceutical Preparations · 115 employees
About Tevogen
TVGN stock →Tevogen Inc., a clinical-stage specialty immunotherapy company, develops off-the-shelf, precision T cell therapies for the treatment of infectious diseases, cancers, and other disorders. The company develops TVGN 489, which has completed Phase 1 clinical trial for the treatment of ambulatory high-risk adult COVID-19 patients; and in Phase 1 clinical trial to treat acute SARS-CoV-2 patients with B-cell cancer immune suppression, and other B cell immune suppressed acute SARS-CoV-2 patients with a B cell cancer indication, as well as Long COVID prevention and treatment.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 18 employees
CELU vs TVGN FAQ
Which is bigger, Celularity or Tevogen?
Celularity (CELU) is larger, with a market capitalization of $49.65M compared with $46.56M for Tevogen (TVGN).
Which stock has performed better over the past year, CELU or TVGN?
CELU returned -32.09% over the past 12 months, compared with -80.50% for TVGN (price return, excluding dividends). Past performance does not predict future results.
Are Celularity and Tevogen in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Pharmaceutical Preparations for Celularity and Biotechnology: Biological Products (No Diagnostic Substances) for Tevogen.